<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002665'>Lymphomas</z:hpo> showing both MYC/8q24 rearrangement and IGH@BCL2/t(14;18)(q32;q21), also referred to as "double-hit" or "dual-hit" <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (DHL) are rare B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> with a germinal center B-cell immunophenotype and <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> cytologic and histologic features </plain></SENT>
<SENT sid="1" pm="."><plain>Such <z:hpo ids='HP_0002665'>lymphomas</z:hpo> may arise de novo or through transformation of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and are classified either as "B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unclassifiable, with features intermediate between diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>)" (most commonly), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, or, rarely, as B-lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We report a case of B-lymphobastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> arising through transformation of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> diagnosed on peritoneal fluid cytology, flow cytometry, and cytogenetic studies in a 53-year-old man who presented with <z:hpo ids='HP_0002027'>abdominal pain</z:hpo>, <z:mp ids='MP_0001954'>shortness of breath</z:mp>, night sweats, extensive <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo>, <z:hpo ids='HP_0002202'>pleural effusion</z:hpo>, and <z:hpo ids='HP_0001541'>ascites</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Cytologic examination of the ascitic fluid showed two distinct populations of neoplastic lymphoid cells, a predominant population of larger cells with fine powdery ("blastic") chromatin, visible to prominent nucleoli and occasional small cytoplasmic vacuoles and a less numerous population of smaller cells with centrocytic <z:mp ids='MP_0000002'>morphology</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Flow cytometry also showed two distinct monotypic B-cell populations, both expressing CD10, and TdT-positivity was demonstrated immunohistochemically </plain></SENT>
<SENT sid="5" pm="."><plain>Fluorescence in situ hybridization (FISH) demonstrated both MYC rearrangement and IGH/BCL2 gene fusion and cytogenetic analysis showed a complex karyotype including both t(14;18)(q32;q21) and t(8;22)(q24.1;q11.2) </plain></SENT>
<SENT sid="6" pm="."><plain>Since DHL pursue an aggressive clinical course, respond poorly to therapy, and have a poor outcome, it is important to suspect the diagnosis when encountering neoplastic lymphoid cells that are difficult to classify in effusion cytology specimens and to order the appropriate immunophenotyping and cytogenetic studies </plain></SENT>
<SENT sid="7" pm="."><plain>Diagn </plain></SENT>
<SENT sid="8" pm="."><plain>Cytopathol. Â© 2012 Wiley Periodicals, Inc </plain></SENT>
</text></document>